HC Wainwright Issues Optimistic Forecast for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities researchers at HC Wainwright boosted their Q2 2025 earnings estimates for shares of Zentalis Pharmaceuticals in a note issued to investors on Thursday, May 15th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.43) for the quarter, up from their previous forecast of ($0.52). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.97) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($2.12) EPS, FY2028 earnings at ($1.50) EPS and FY2029 earnings at ($0.57) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.67).

Other analysts also recently issued reports about the stock. Wells Fargo & Company lowered their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. UBS Group lowered their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Wedbush reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Zentalis Pharmaceuticals currently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL opened at $1.26 on Monday. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $13.00. The company has a market capitalization of $90.66 million, a PE ratio of -0.51 and a beta of 1.81. The firm’s 50 day moving average is $1.44 and its 200-day moving average is $2.33.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC raised its stake in Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after acquiring an additional 2,111,951 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Zentalis Pharmaceuticals by 50.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 348,965 shares of the company’s stock valued at $555,000 after buying an additional 116,907 shares during the period. AQR Capital Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 177.6% in the first quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock valued at $985,000 after buying an additional 396,233 shares during the period. Almitas Capital LLC increased its position in Zentalis Pharmaceuticals by 5.2% during the 1st quarter. Almitas Capital LLC now owns 1,710,921 shares of the company’s stock valued at $2,720,000 after purchasing an additional 84,025 shares during the period. Finally, Alpine Global Management LLC acquired a new stake in Zentalis Pharmaceuticals during the 1st quarter valued at approximately $48,000.

Insider Activity

In other news, Director Scott Dunseth Myers acquired 21,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The stock was acquired at an average price of $1.40 per share, with a total value of $29,400.00. Following the completion of the transaction, the director now directly owns 281,192 shares of the company’s stock, valued at $393,668.80. This trade represents a 8.07% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is currently owned by company insiders.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.